Table of Content

1 Global Acellular Therapy Market: Strategic Overview
1.1 Acellular Therapy: Overview
1.2 Stem Cell Therapy
1.2.1 Extracellular Vesicles
1.2.2 Cell-Free Therapy with Extracellular Vesicles
1.3 Cell Therapy vs. Cell-Free Therapy
1.3.1 Advantages of Cell Therapy and Cell-Free Therapy
1.3.2 Risks and Limitations of Cell Therapy and Cell-Free Therapy
1.3.2.1 Challenges and Risks Associated with Stem Cell-Based Therapy in Regenerative Medicine
1.3.2.2 Challenges and Risks Associated with Cell-Free Therapies:
1.4 Application of Extracellular Vesicles (EVs) in Regenerative Medicine
1.4.1.1 Cardiology
1.4.1.2 Hepatology
1.4.1.3 Neurology
1.4.1.4 Gastroenterology
1.4.1.5 Oncology
1.5 Acellular Therapy: A Novel Approach for COVID-19
1.5.1 COVID-19 Therapeutic Strategies Involving the MSC Secretome
1.5.2 Extracellular Vesicles Used in COVID-19 for Several Reasons
1.6 Expert Insights
1.7 Clinical Trial Analysis: Acellular Therapy
1.7.1 Acellular Therapy Pipeline Analysis
1.7.2 Acellular Therapy Clinical Trial Design
1.7.2.1 ExoFlo
1.7.2.1.1 Product Profile
1.7.2.1.2 ExoFlo Phase II Study Design
1.8 Extracellular Vesicles-Based Therapeutics: Regulatory Aspects
1.8.1 Regulatory Frameworks in the U.S.
1.8.2 Regulatory Frameworks in Europe
1.8.3 Regulatory Frameworks in Canada
1.8.4 Regulatory Frameworks in Japan
1.8.5 Regulatory Frameworks in Australia
1.8.6 Regulatory Frameworks in South Korea
1.8.7 Challenges Prior to Clinical Translation
1.9 Competitive Landscape
1.9.1 Clinical Developments
1.9.2 Regulatory and Legal Activities
1.9.3 Partnerships and Alliances
1.9.4 Funding Activities
1.9.5 Business Expansions
1.1 Company Profiles
1.10.1 Overview
1.10.2 Aegle Therapeutics Corp
1.10.2.1 Company Overview
1.10.2.2 Role of Aegle Therapeutics Corp in the Acellular Therapy Market
1.10.2.3 Business Strategies
1.10.2.4 SWOT Analysis
1.10.3 ArunA Biomedical
1.10.3.1 Company Overview
1.10.3.2 Role of ArunA Biomedical in the Acellular Therapy Market
1.10.3.3 Business Strategies
1.10.3.4 SWOT Analysis
1.10.4 Capricor Therapeutics, Inc.
1.10.4.1 Company Overview
1.10.4.2 Role of Capricor Therapeutics, Inc. in the Acellular Therapy Market
1.10.4.3 Business Strategies
1.10.4.4 SWOT Analysis
1.10.5 Codiak BioSciences, Inc.
1.10.5.1 Company Overview
1.10.5.2 Role of Codiak BioSciences, Inc. in the Acellular Therapy Market
1.10.5.3 Financials
1.10.5.4 Key Insights About Financial Health of the Company
1.10.5.5 Business Strategies
1.10.5.6 SWOT Analysis
1.10.6 Direct Biologics, LLC
1.10.6.1 Company Overview
1.10.6.2 Role of Direct Biologics, LLC in the Acellular Therapy Market
1.10.6.3 Business Strategies
1.10.6.4 SWOT Analysis
1.10.7 EV Therapeutics, Inc.
1.10.7.1 Company Overview
1.10.7.2 Role of EV Therapeutics in the Acellular Therapy Market
1.10.7.3 SWOT Analysis
1.10.8 Evox Therapeutics Ltd
1.10.8.1 Company Overview
1.10.8.2 Role of Evox Therapeutics Ltd in the Acellular Therapy Market
1.10.8.3 Business Strategies
1.10.8.4 SWOT Analysis
1.10.9 Exogenus Therapeutics
1.10.9.1 Company Overview
1.10.9.2 Role of Exogenus Therapeutics in the Acellular Therapy Market
1.10.9.3 Business Strategies
1.10.9.4 SWOT Analysis
1.10.10 Invitrx Therapeutics, Inc.
1.10.10.1 Company Overview
1.10.10.2 Role of Invitrx Therapeutics, Inc. in the Acellular Therapy Market
1.10.10.3 SWOT Analysis
1.10.11 Organicell Regenerative Medicine, Inc.
1.10.11.1 Company Overview
1.10.11.2 Role of Organicell Regenerative Medicine, Inc. in the Acellular Therapy Market
1.10.11.3 Business Strategies
1.10.11.4 SWOT Analysis
1.10.12 Rion LLC
1.10.12.1 Company Overview
1.10.12.2 Role of Rion LLC in the Acellular Therapy Market
1.10.12.3 SWOT Analysis
1.10.13 Stem Cell Medicine Ltd.
1.10.13.1 Company Overview
1.10.13.2 Role of Stem Cell Medicine Ltd. in the Acellular Therapy Market
1.10.13.3 Business Strategies
1.10.13.4 SWOT Analysis
List of Figures
Figure 1: Count of Published Research Papers for Acellular, Cell-Free, and Exosome-Based Therapy (Since 2015)
Figure 2: Count of Clinical Trial for Cell-Free or Exosome-Based Therapies (as of March 2022)
Figure 3: Global Acellular Therapy Market: Segmentation
Figure 4: Function of Mesenchymal Stem Cells (MSCs)
Figure 5: Hierarchy of Cell-Based and Cell-Free Therapy
Figure 6: Three Major Classes of Extracellular Vesicles (EVs)
Figure 7: Advantages of Cell-Based and Cell-Free Therapy
Figure 8: Risk Factors with Stem Cell Therapy (SCT)
Figure 9: Clinical Risks with Stem Cell Therapy (SCT)
Figure 10: Extracellular Vesicles (EVs): Potential Therapeutic Tool for Several Disease Areas
Figure 11: Properties of Mesenchymal Stem Cells (MSCs) Secretome
Figure 12: Advantages, Challenges, and Clinical Applications of Cell-Based and Cell-Free Therapy
Figure 13: Number of Clinical Trials by Academic Institutions and Biopharmaceutical Companies
Figure 14: Acellular Drugs Clinical Trials (by Phase), 2022
Figure 15: Acellular Drugs Global Clinical Trials (by Indication), 2022
Figure 16: ExoFlo Phase II Clinical Trial Design for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS)
Figure 17: ExoFlo Phase II Clinical Trial Arms and Interventions for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS)
Figure 18: ExoFlo Phase II Clinical Trial Design for Mild-to-Moderate COVID-19
Figure 19: ExoFlo Phase II Clinical Trial Arms and Interventions for Mild-to-Moderate COVID-19
Figure 20: Three Factors Determine the Regulatory Status of hMSC-Based Products
Figure 21: Challenges Prior to Clinical Translation
Figure 22: Share of Key Developments and Strategies, January 2018-March 2022
Figure 23: Share of Clinical Developments (by Company), January 2018-March 2022
Figure 24: Share of Regulatory and Legal Activities (by Company), January 2018-March 2022
Figure 25: Share of Partnerships and Alliances (by Company), January 2018-March 2022
Figure 26: Share of Funding Activities (by Company), January 2018-March 2022
Figure 27: Share of Business Expansions (by Company), January 2018-March 2022
Figure 28: Aegle Therapeutics Corp: Product Portfolio
Figure 29: Aegle Therapeutics Corp: SWOT Analysis
Figure 30: ArunA Biomedical: Product Portfolio
Figure 31: ArunA Biomedical: SWOT Analysis
Figure 32: Capricor Therapeutics, Inc.: Product Portfolio
Figure 33: Capricor Therapeutics, Inc.: SWOT Analysis
Figure 34: Codiak BioSciences Inc.: Product Portfolio
Figure 35: Codiak BioSciences, Inc.: Overall Financials/Revenue, $Million, 2019-2021
Figure 36: Codiak BioSciences, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 37: Codiak BioSciences, Inc.: R&D Expenditure (by Product), $Million, 2019-2021
Figure 38: Codiak BioSciences, Inc.: SWOT Analysis
Figure 39: Direct Biologics, LLC: Product Portfolio
Figure 40: Direct Biologics, LLC: SWOT Analysis
Figure 41: EV Therapeutics, Inc.: Product Portfolio
Figure 42: EV Therapeutics, Inc.: SWOT Analysis
Figure 43: Evox Therapeutics Ltd: Product Portfolio
Figure 44: Evox Therapeutics Ltd: SWOT Analysis
Figure 45: Exogenus Therapeutics: Product Portfolio
Figure 46: Exogenus Therapeutics: SWOT Analysis
Figure 47: Invitrx Therapeutics, Inc.: Product Portfolio
Figure 48: Invitrx Therapeutics, Inc.: SWOT Analysis
Figure 49: Organicell Regenerative Medicine, Inc.: Product Portfolio
Figure 50: Organicell Regenerative Medicine, Inc.: SWOT Analysis
Figure 51: Rion LLC: Product Portfolio
Figure 52: Rion LLC: SWOT Analysis
Figure 53: Stem Cell Medicine Ltd.: Product Portfolio
Figure 54: Stem Cell Medicine Ltd.: SWOT Analysis
List of Tables
Table 1: Cell Therapies Vs. Cell-Free Therapies
Table 2: Emerging Acellular Drugs Pipeline
Table 3: Regulatory Proteins in ExoFlo